Involving Nonmembrane Bound Receptor Binding Or Protein Binding Other Than Antigen-antibody Binding Patents (Class 435/7.8)
-
Publication number: 20140220595Abstract: Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme's ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.Type: ApplicationFiled: June 8, 2012Publication date: August 7, 2014Applicant: Shire Human Genetic Therapies, Inc.Inventor: Daniel S. Roseman
-
Publication number: 20140220596Abstract: The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: Medicinal Bioconvergence Research CenterInventors: Sunghoon KIM, Min Chul Park
-
Patent number: 8790883Abstract: The present invention relates to polypeptides that inhibit the NF-?B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.Type: GrantFiled: April 24, 2008Date of Patent: July 29, 2014Assignee: Institut PasteurInventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Vernon, Francois Traincard, Shoji Yamaoka
-
Patent number: 8785141Abstract: The invention aims at providing an adsorbent for bacterial toxins, a method for removal of such toxins by adsorption, and an adsorber packed with said adsorbent. Provided are an adsorbent for bacterial toxins, which comprises a water-insoluble porous material having a mode of pore radius of 20 angstroms to 1,000 angstroms, a method for removal of bacterial toxins using said adsorbent, and an adsorber packed with said adsorbent.Type: GrantFiled: August 24, 2001Date of Patent: July 22, 2014Assignee: Kaneka CorporationInventors: Tamiji Fujimoto, Fumiyasu Hirai, Shigeo Furuyoshi
-
Patent number: 8765488Abstract: Sensing compositions, sensing element, sensing systems and sensing devices for the detection and/or quantitation of one or more analytes, Compositions comprising carbon nanotubes in which the carbon nanotubes retain their ability to luminesce and in which that luminescence is rendered selectively sensitive to the presence of an analyte. Compositions comprising individually dispersed carbon nanotubes, which are electronically isolated from other carbon nanotubes, yet which are associated with chemical selective species, such as polymers, particularly biological polymers, for example proteins, which can interact selectively with, or more specifically selectivity bind to, an analyte of interest. Chemically selective species bind, preferably non-covalently, to the carbon nanotube and function to provide for analyte selectivity. Chemically selective species include polymers to which one or more chemically selective groups are covalently attached.Type: GrantFiled: July 22, 2005Date of Patent: July 1, 2014Assignee: The Board of Trustees of the University of IllinoisInventors: Michael S. Strano, Seunghyun Baik, Paul Barone
-
Publication number: 20140179593Abstract: Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl).Type: ApplicationFiled: May 16, 2012Publication date: June 26, 2014Applicant: St. Jude Children's Research HospitalInventors: Julie K. Monda, Brenda A. Schulman, Daniel C. Scott
-
Publication number: 20140179608Abstract: Described herein are methods to bind a compound to the SH2 domain of Src in a Src-expressing cell which includes contacting a compound comprising an amino acid compound to a Src-expressing cell; and binding a compound to the SH2 domain of Src.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Zi-Jian Xie, Qiqi Ye, Zhichuan Li
-
Patent number: 8753830Abstract: Cdc25A is herein identified as a substrate for ?-TrCP1- or ?-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with ?-TrCP expression or function, or increasing ?-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying ?-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.Type: GrantFiled: May 3, 2013Date of Patent: June 17, 2014Assignee: New York UniversityInventors: Michele Pagano, Luca Busino
-
Publication number: 20140162288Abstract: The present invention provides biomarkers for replicative senescence. In particular, Lamin B1 is provided as a biomarker for replicative senescence.Type: ApplicationFiled: December 6, 2013Publication date: June 12, 2014Applicant: NORTHWESTERN UNIVERSITYInventors: Robert D. Goldman, Takeshi Shimi, Stephen A. Adam
-
Publication number: 20140162287Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.Type: ApplicationFiled: July 16, 2013Publication date: June 12, 2014Inventor: Jeffrey Garwin
-
Publication number: 20140165222Abstract: The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.Type: ApplicationFiled: March 8, 2012Publication date: June 12, 2014Applicant: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNEInventor: Manuel Salvador Rodriguez Medina
-
Publication number: 20140161729Abstract: The present invention is directed to method of using a collection of monomers capable of forming multimers as a fluorescence reporter in different applications such as ligand detection/screening, disease diagnosis, drug discovery or screening, fluorescent labeling and imaging, or other fluorescent methodologies. Each monomer in the collection includes one or more ligand elements useful for binding to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the ligand elements directly or indirectly through a connector. Association of linker elements of different combinations of monomers, with their ligand elements bound to the target molecule to form a multimer, will generate a unique fluorescent signature different from that produced by those monomers either alone or in association with each other in the absence of the target molecule, when subjected to electromagnetic excitement.Type: ApplicationFiled: April 9, 2012Publication date: June 12, 2014Applicant: CORNELL UNIVERSITYInventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
-
Publication number: 20140142120Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: ApplicationFiled: October 16, 2013Publication date: May 22, 2014Applicant: NEW YORK UNIVERSITYInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Publication number: 20140134641Abstract: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.Type: ApplicationFiled: September 19, 2013Publication date: May 15, 2014Applicant: Helion Biotech ApSInventors: Jens Chr. Jensenius, Steffen Thiel
-
Publication number: 20140134642Abstract: The present invention relates to a method of characterizing biochips with matrix-assisted laser desorption/ionization and time of flight mass spectrometry (MALDI-TOF MS).Type: ApplicationFiled: January 21, 2014Publication date: May 15, 2014Applicant: THE UNIVERSITY OF CHICAGOInventors: Milan MRKSICH, Jing SU
-
Publication number: 20140128316Abstract: The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.Type: ApplicationFiled: September 18, 2013Publication date: May 8, 2014Inventors: Zeger DEBYSER, Petr Cherepanov, Erik De Clercq
-
Publication number: 20140113312Abstract: A method is disclosed for classifying and distinguishing between type I and type II kinase inhibitors. The method involves the use of non-linear optical techniques, in particular second-harmonic generation (SHG) to identify conformational changes in kinase proteins obtained from known type I or type II inhibitors. The method further involves deducing the manner of binding of unknown inhibitors by comparison with the signal changes produced by known ligands. The method is also applied to comparing the conformational changes induced by the binding of generic and branded kinase inhibitor drugs to a target kinase.Type: ApplicationFiled: March 21, 2012Publication date: April 24, 2014Applicant: Biodesy, Inc.Inventors: Joshua S. Salafsky, Ryan McGuinness
-
Patent number: 8685752Abstract: The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula Ab-X, wherein the group Ab comprises a ligand that binds to the pathogenic cells and the group X comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.Type: GrantFiled: November 2, 2007Date of Patent: April 1, 2014Assignee: Purdue Research FoundationInventors: Philip Stewart Low, Wei He, Sumith A Kularatne
-
Patent number: 8685658Abstract: Compositions and methods are provided for identifying agents which have efficacy for the treatment of disorders related to aberrant cilial structure and function, including polycystic kidney disease.Type: GrantFiled: July 17, 2007Date of Patent: April 1, 2014Assignee: Fox Chase Cancer CenterInventors: Erica A. Golemis, Elena N. Pugacheva
-
Patent number: 8673584Abstract: A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent includes a neutral carbon center or include an oxygen, sulfur, selenium, or other atom with similar physiochemical properties; (c) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent is devoid of an electropositive atom or substituents; or (d) a second terminal substituent opposite of the first terminal substituent, said second terminal substituent having an atom that is a hydrogen boding acceptor and/or is negatively charged.Type: GrantFiled: November 13, 2012Date of Patent: March 18, 2014Assignees: University of Kansas, Florida Memorial UniversityInventors: Gerald Carlson, Todd Holyoak, Sarah Sullivan, Rose Mary Stiffin
-
Patent number: 8673558Abstract: A modified beetle luciferase protein which is an environmentally sensitive reporter protein is provided.Type: GrantFiled: April 24, 2012Date of Patent: March 18, 2014Assignee: Promega CorporationInventors: Frank Fan, Martin Ken Lewis, John W. Shultz, Keith V. Wood, Braeden Butler
-
Publication number: 20140072956Abstract: A composition includes a first probe capable of binding to a first analyte and a first initiator bonded to the first probe. The composition further includes a second probe capable of binding to a second analyte and a second initiator bonded to the second probe. At least one of the first initiator or the second initiator is capable of initiating a controlled polymerization reaction. An associated kit, device, and method are provided.Type: ApplicationFiled: February 28, 2007Publication date: March 13, 2014Applicant: General Electric CompanyInventors: Su Lu, John Yupeng Gui, Bahram Moasser, Wei Cai, Zhixin Zheng, John Richard Nelson
-
Publication number: 20140073639Abstract: The application describes targets and methods that can inhibit bacterial growth in Gram-positive and Gram-negative bacteria. A bacterial enzyme, 2-epimerase, is common to both Gram-positive and Gram-negative bacteria and contains an allosteric site that can be targeted to disrupt the enzyme. The allosteric site is present on the bacterial 2-epimerase, but the analogous mammalian enzyme does not contain the allosteric site, providing a route for attacking bacterial infections without affecting the mammalian enzyme.Type: ApplicationFiled: August 8, 2013Publication date: March 13, 2014Applicants: The Rockefeller University, Avacyn Pharmaceuticals, Inc.Inventors: Vincent A. FISCHETTI, Allan R. GOLDBERG, Raymond SCHUCH
-
Publication number: 20140051095Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).Type: ApplicationFiled: October 24, 2013Publication date: February 20, 2014Applicant: Mologic LTDInventor: Paul J. Davis
-
Patent number: 8652796Abstract: The present invention provides methods and compositions for detecting protein-protein and/or protein-nucleic acid interactions in cells.Type: GrantFiled: September 17, 2007Date of Patent: February 18, 2014Assignee: President and Fellows of Harvard CollegeInventors: Max L. Nibert, Cathy Lea Miller, Teresa J. Broering
-
Publication number: 20140044796Abstract: The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.Type: ApplicationFiled: February 10, 2012Publication date: February 13, 2014Applicant: OXPROTECT GMBHInventors: Beate Kehrel, Martin Brodde
-
Publication number: 20140045193Abstract: The invention relates to the use of enzymes and nanorods to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. This invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject and treating the subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage.Type: ApplicationFiled: August 9, 2013Publication date: February 13, 2014Applicant: Cedars-Sinai Medical CenterInventors: Neil A. Bhowmick, Diptiman Choudhury
-
Patent number: 8647828Abstract: The present invention provides methods for intracellular and/or nuclear targeting of an agent capable of specifically binding to syndecan-4. The present invention further provides methods for the modification of the intracellular and/or nuclear targeting of said agent, as well methods for identifying compounds capable of modifying the syndecan-4 delivery pathway. The present invention further provides experimental kits to perform the methods according to the invention.Type: GrantFiled: July 12, 2007Date of Patent: February 11, 2014Assignee: Szilak Laboratories Bioinformatics & Molecule-Design Ltd.Inventors: László Szilák, Anikó Keller-Pintér, József Tímár, Tamás Letoha
-
Patent number: 8647834Abstract: Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.Type: GrantFiled: December 13, 2011Date of Patent: February 11, 2014Assignee: Probiodrug AGInventors: Stephan Schilling, Holger Cynis, Jens-Ulrich Rahfeld, Hans-Ulrich Dermuth
-
Publication number: 20140038205Abstract: The invention provides methods and compositions relating to the detection and neutralization of heparin and heparin derivatives in vivo and in vitro. To neutralize heparin in a patient sample, a composition comprising a complex of a heparin-binding agent and a carrier compound is used prior to performing coagulation assays.Type: ApplicationFiled: January 18, 2012Publication date: February 6, 2014Applicant: Precision BioLogic Inc.Inventor: Steven Jay Raynard
-
Patent number: 8642281Abstract: Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide.Type: GrantFiled: April 5, 2011Date of Patent: February 4, 2014Assignees: JNC Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Satoshi Inouye, Yuiko Sahara, Takamitsu Hosoya
-
Publication number: 20140030294Abstract: The invention provides, e.g., compositions and methods for increasing activation of immune cells.Type: ApplicationFiled: February 7, 2012Publication date: January 30, 2014Applicant: CORNELL UNIVERSITYInventor: Laurie H. Glimcher
-
Publication number: 20140024648Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: ApplicationFiled: March 6, 2012Publication date: January 23, 2014Applicant: BIOTIE THERAPIES CORPORATIONInventors: Marjo Pihlavisto, David Smith, Auni Juhakoski, Ferenc Fulop, Laszlo Lazar, Istvan Szatmari, Ferenc Miklos, Zsolt Szakonyi, Lorand Kiss, Marta Palko
-
Patent number: 8632990Abstract: The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders.Type: GrantFiled: December 15, 2011Date of Patent: January 21, 2014Assignee: Siemens Healthcare Diagnostics Inc.Inventor: Michael Pugia
-
Publication number: 20140018287Abstract: It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance.Type: ApplicationFiled: March 19, 2012Publication date: January 16, 2014Inventors: Richard H. Ebright, David Degen, Katherine Y. Ebright
-
Patent number: 8629251Abstract: The present invention is related to the field of phospholipid detection. In particular, certain embodiments provide the detection of phosphatidic acid. For example, certain proteins are capable of binding phosphatidic acid and can be used as a diagnostic and/or research tool to identify and quantitate phosphatidic acid. Phosphatidic acid may be in or from cells and tissues isolated from plants, animals and humans. For example, a trigalactosyldiacylglycerol-2 (TGD2) protein may be fused with a fluorescent probe to monitor and measure phosphatidic acid in vitro as well as in vivo. In other embodiments, a trigalactosyldiacylglycerol-4 (TGD4) protein may be fused with a fluorescent probe to monitor and measure phosphatidic acid in vitro as well as in vivo. In additional embodiments, a fragment comprising either a truncated TGD2 or TGD4 phosphatidic acid binding region protein may be used to monitor or measure phosphatidic acid.Type: GrantFiled: January 13, 2012Date of Patent: January 14, 2014Assignee: Board of Trustees of Michigan State UniversityInventors: Christoph Benning, Zhen Wang
-
Patent number: 8623605Abstract: The invention provides a method of diagnosis of a spongiform encephalopathy in a diagnostic sample of a valid body tissue taken from a subject, which comprises detecting an increased proteolytic activity in the diagnostic sample, compared with a sample from a control subject.Type: GrantFiled: May 29, 2007Date of Patent: January 7, 2014Assignee: Electrophoretics LimitedInventors: Ian Hugo Pike, Malcolm Andrew Ward, Darragh Patrick William O'Brien
-
Patent number: 8623608Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.Type: GrantFiled: January 13, 2012Date of Patent: January 7, 2014Assignees: Sysmex Corporation, National Institute of Advanced Industrial Science and Technology, Nagoya University, National Center for Global Health and MedicineInventors: Hisashi Narimatsu, Yuzuru Ikehara, Atsushi Kuno, Maki Sogabe, Yasuhito Tanaka, Masashi Mizokami, Kiyoaki Ito, Shunsuke Matsubara, Chikayuki Tsuruno, Youichi Takahama, Takashi Kagawa, Shinya Nagai
-
Patent number: 8623324Abstract: Chemically reactive dyes that are intramolecularly crosslinked with a water-soluble bridge, their bioconjugates and their uses are described. Reactive fluorescent dyes that have a water-soluble bridge are superior to those of conjugates of spectrally non-crosslinked dyes or the dyes that are crosslinked with a hydrophobic bridge. The invention includes reactive fluorescent dyes, their biological conjugates and uses.Type: GrantFiled: July 12, 2011Date of Patent: January 7, 2014Assignees: AAT Bioquest Inc., Becton, Dickinson and CompanyInventors: Timothy Dubrovsky, Barnaby Abrams, Zhenjun Diwu, Qinglin Meng, Jinfang Liao, Haitao Guo
-
Publication number: 20140004532Abstract: The present invention relates to isolated raptor nucleic acid molecules of mammalian origin (e.g., human) and complements, portions and variants thereof. Another aspect of the invention are isolated raptor polypeptides of mammalian origin and portions thereof, and antibodies or antigen binding fragments thereof that specifically bind a raptor polypeptide. The present invention also relates to constructs and host cells comprising the nucleic acid molecules described herein. In addition, the present invention relates to uses of the nucleic acid and polypeptide molecules provided herein.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Whitehead Institute For Biomedical ResearchInventors: David M. Sabatini, Do-Hyung Kim, Dos Sarbassov
-
Patent number: 8617833Abstract: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-?36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.Type: GrantFiled: August 7, 2012Date of Patent: December 31, 2013Assignee: Creighton UniversityInventor: Zhao Yi Wang
-
Publication number: 20130331317Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: March 15, 2013Publication date: December 12, 2013Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina Goetz
-
Publication number: 20130331325Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: March 15, 2013Publication date: December 12, 2013Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20130323747Abstract: The present invention relates to a method of detecting the presence, amount or subcellular location of an antigenic structure of interest in a cell.Type: ApplicationFiled: May 20, 2013Publication date: December 5, 2013Applicant: Ludwig-Maximilians-Universitat MunchenInventors: Ulrich Rothbauer, Heinrich Leonhardt
-
Publication number: 20130309252Abstract: The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.Type: ApplicationFiled: February 2, 2012Publication date: November 21, 2013Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Michel Aurrand-Lions, Ana Zarubica
-
Publication number: 20130295563Abstract: The present invention relates to nanoparticles in the shape of nanosnowman with a head part and a body part, a preparation method thereof, and a detection method using the same. More particularly, the present invention relates to nanoparticles in the shape of nanosnowman with head and body parts, which can offer platforms for DNA-based assembly of various aligned and unconventional nanostructures and is highly applicable to the detection of DNA and an analyte associated with the onset and progression of a particular disease, a preparation method thereof, and a detection method using the same.Type: ApplicationFiled: March 6, 2013Publication date: November 7, 2013Inventors: Jwa Min NAM, Jung Hoon Lee, Jeong Wook Oh
-
Patent number: 8574862Abstract: Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.Type: GrantFiled: May 3, 2010Date of Patent: November 5, 2013Assignee: Cytochrama Inc.Inventors: P. Martin Petkovich, Christian F. Helvig
-
Publication number: 20130288271Abstract: The present invention discloses, inter alia, methods for labeling a target protein with an SHG-active probe for detection by second harmonic or sum-frequency generation in order to identify agents which bind to an allosteric site on the target protein thereby altering its structural conformationType: ApplicationFiled: March 11, 2013Publication date: October 31, 2013Inventor: Joshua S. SALAFSKY
-
Publication number: 20130280247Abstract: A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9. Molecules capable of specifically interacting with the OG domain, methods of identifying same, pharmaceutical compositions comprising same and uses thereof are also disclosed.Type: ApplicationFiled: June 13, 2013Publication date: October 24, 2013Inventors: Irit SAGI, Gabriel Rosenblum
-
Patent number: 8563263Abstract: The present invention is directed to a composition comprising a vanadium-containing phosphatase inhibitor and a polyol. In the presence of the polyol the effect of the inhibitor is enhanced, even in the presence of chelating agents or reducing agents. The invention also concerns the use of the inventive composition for inhibiting a phosphatase, as well as kits comprising the composition.Type: GrantFiled: August 29, 2012Date of Patent: October 22, 2013Assignee: Roche Diagnostics Operations Inc.Inventors: Erhard Fernholz, Dorothea Mayr